



Human Papillomavirus Vaccine against Cervical Cancer and Beyond: Opportunities, Challenges and New Perspectives

Guest Editors:

Dr. Rosa De Vincenzo

Dr. Alessandro Ghelardi

Dr. Ankica Lukic

Dr. Caterina Ricci

Deadline for manuscript
submissions:
closed (30 June 2021)

Message from the Guest Editors

Dear Colleagues,

We are soliciting articles for a Special Issue of MDPI *Vaccines*, which will be entitled “Human Papillomavirus Vaccine against Cervical Cancer and Beyond: Opportunities, Challenges and New Perspectives”.

It is now well known that Human Papilloma Virus (HPV) infection can lead to the development of genital warts, as well as cervical, anogenital, and oropharyngeal cancer. The World Health Organization (WHO) has recognized the importance of HPV-related diseases as a global public health issue, promoting HPV vaccination all over the world. Therefore, since 2006, many countries have implemented publicly funded HPV immunization programs, first targeting female adolescents and then progressively expanding HPV vaccination campaigns. Following the growing evidence of HPV-related diseases also in males, vaccines were then extended from female-only to gender-neutral populations. However, cervical cancer still remains a significant public health burden that requires further research work. Increasing awareness and understanding about the clinical value of vaccination, as well as extended investigations on emerging features of this HPV-related cancer, are needed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)